Teva gets a taste of its own patent-challenge medicine

Teva Pharmaceutical Industries, the generic-drug giant that made a business out of challenging the valuable patents of Big Pharma, is getting a taste of its own tactics as generics makers target its multiple sclerosis drug Copaxone. And it's adopting the same defensive tactics that branded drugmakers have employed against it for years. Report

Suggested Articles

Allergan was willing to part with candidate brazikumab to pass FTC muster, but union and consumer groups say that sale won't amend antitrust worries.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)

BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.